Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2004 1
2005 3
2006 1
2007 1
2008 3
2009 4
2010 1
2011 3
2012 6
2013 8
2014 10
2015 11
2016 9
2017 6
2018 3
2019 2
2020 1
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28415715

64 results

Results by year

Filters applied: . Clear all
Page 1
Epha3 acts as proangiogenic factor in multiple myeloma.
Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D. Caivano A, et al. Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100. Oncotarget. 2017. PMID: 28415715 Free PMC article.
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A. La Rocca F, et al. Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18. Cell Oncol (Dordr). 2017. PMID: 28721629 Free article.
A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, Ribatti D, Vacca A. Ferrucci A, et al. Clin Cancer Res. 2014 Nov 15;20(22):5796-807. doi: 10.1158/1078-0432.CCR-14-0847. Epub 2014 Sep 11. Clin Cancer Res. 2014. PMID: 25212607
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R, Catacchio I, Berardi S, De Luisi A, Caivano A, Piccoli C, Ruggieri V, Frassanito MA, Ribatti D, Nico B, Annese T, Ruggieri S, Guarini A, Minoia C, Ditonno P, Angelucci E, Derudas D, Moschetta M, Dammacco F, Vacca A. Ria R, et al. Clin Cancer Res. 2014 Feb 15;20(4):847-58. doi: 10.1158/1078-0432.CCR-13-1950. Epub 2013 Dec 2. Clin Cancer Res. 2014. PMID: 24297864
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?
Saltarella I, Frassanito MA, Lamanuzzi A, Brevi A, Leone P, Desantis V, Di Marzo L, Bellone M, Derudas D, Ribatti D, Chiaramonte R, Palano MT, Neri A, Mariggiò MA, Fumarulo R, Dammacco F, Racanelli V, Vacca A, Ria R. Saltarella I, et al. Neoplasia. 2019 Jan;21(1):93-105. doi: 10.1016/j.neo.2018.10.011. Epub 2018 Dec 5. Neoplasia. 2019. PMID: 30529074 Free PMC article.
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
Berardi S, Caivano A, Ria R, Nico B, Savino R, Terracciano R, De Tullio G, Ferrucci A, De Luisi A, Moschetta M, Mangialardi G, Catacchio I, Basile A, Guarini A, Zito A, Ditonno P, Musto P, Dammacco F, Ribatti D, Vacca A. Berardi S, et al. Oncogene. 2012 May 3;31(18):2258-69. doi: 10.1038/onc.2011.412. Epub 2011 Oct 3. Oncogene. 2012. PMID: 21963844
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, Guarini A, Ranieri G, Ditonno P, Berardi S, Caivano A, Basile A, Cascavilla N, Capalbo S, Quarta G, Dammacco F, Ribatti D, Vacca A. De Luisi A, et al. Clin Cancer Res. 2011 Apr 1;17(7):1935-46. doi: 10.1158/1078-0432.CCR-10-2381. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307145
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A. Basile A, et al. J Pathol. 2013 Jan;229(1):87-98. doi: 10.1002/path.4081. Epub 2012 Oct 1. J Pathol. 2013. PMID: 22847671 Free article.
64 results